CIQ

SKU: orb1308448

Description

CIQ is a small molecule that selectively potentiates NMDA receptors incorporating the NR2C or NR2D subunit, with EC50 values of 2.7 μM and 2.8 μM, respectively. It serves as a valuable research tool for investigating the specific roles of these receptor subtypes in synaptic plasticity, neurological disorders, and related in vitro and in vivo models.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 486427-17-2
• MW: 467.94
• Purity: 99.50%
• Formula: C₂₆H₂₆ClNO₅
• SMILES: COc1ccc(OCC2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1
• Target: iGluR,NMDAR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.27 mM);DMSO:50 mg/mL (106.85 mM);H2O:insoluble

Bioactivity

• Target IC50:
  NR2C:2.7 μM(EC50)|NR2D:2.8 μM(EC50)
• In Vitro:
  CIQ reduces associated behaviours in schizophrenia models and potentially enhances dopamine release in Parkinson's disease models. NMDA receptor CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively). It has no effect on NR2A or NR2B subtypes. CIQ does not alter the EC50 values for glutamate or glycine on channel opening. CIQ increases channel opening efficiency and enhances NMDA receptor responses.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CIQ, inhibit, Ionotropic glutamate receptors, Inhibitor, NMDA, iGluR

Compound Identifiers

PubChem CID

4231127